BiotechTube

Inclisiran + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Familial Hypercholesterolemia - Heterozygous

Conditions

Familial Hypercholesterolemia - Heterozygous

Trial Timeline

Jan 27, 2021 → Nov 27, 2024

NCT ID
NCT04652726

About Inclisiran + Placebo

Inclisiran + Placebo is a phase 3 stage product being developed by Novartis for Familial Hypercholesterolemia - Heterozygous. The current trial status is completed. This product is registered under clinical trial identifier NCT04652726. Target conditions include Familial Hypercholesterolemia - Heterozygous.

What happened to similar drugs?

5 of 20 similar drugs in Familial Hypercholesterolemia - Heterozygous were approved

Approved (5) Terminated (4) Active (13)
✅EvolocumabAmgenApproved
✅evolocumabAmgenApproved
✅AnakinraSwedish Orphan BiovitrumApproved
✅Colesevelam hydrochloride film-coated tablets + PlaceboSanofiApproved
✅PraluentSanofiApproved
🔄SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT06597006Phase 3Recruiting
NCT06597019Phase 3Recruiting
NCT04659863Phase 3Completed
NCT04652726Phase 3Completed
NCT03705234Phase 3Active

Competing Products

20 competing products in Familial Hypercholesterolemia - Heterozygous

See all competitors
ProductCompanyStageHype Score
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
SHR-1209Jiangsu Hengrui MedicinePhase 2
31
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
40
Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
40
rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calciumAstraZenecaPhase 3
40
Rosuvastatin + PlaceboAstraZenecaPhase 3
40
Rosuvastatin 20mgAstraZenecaPhase 3
40
AZD0780 + PlaceboAstraZenecaPhase 3
44
Anacetrapib + Placebo for anacetrapibMerckPhase 3
40
Statins and EzetimibeMerckPre-clinical
22
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placeboMerckPhase 3
32
MK-0524A + MK-0524AMerckPhase 1
21
Enlicitide Decanoate + PlaceboMerckPhase 2/3
45
Inclisiran + PlaceboNovartisPhase 3
40
DFV890NovartisPhase 2
35
CanakinumabNovartisPhase 2
35
Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
40
LCQ908 + PlaceboNovartisPhase 3
40
InclisiranNovartisPhase 3
44
FluvastatinNovartisPhase 3
40